Effect of clopidrogel plus aspirin on tissue perfusion and coronary flow in patients with ST-segment elevation myocardial infarction: A new reperfusion strategy

被引:6
作者
Dogan, A [1 ]
Ozgul, M [1 ]
Ozaydin, M [1 ]
Aslan, SM [1 ]
Gedikli, O [1 ]
Altinbas, A [1 ]
机构
[1] Suleyman Demirel Univ, Dept Cardiol, Sevket Demirel Heart Ctr, TR-32100 Isparta, Turkey
关键词
D O I
10.1016/j.ahj.2004.10.039
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Current reperfusion strategies may fail to achieve optimal tissue perfusion in ST-elevation myocardial infarction (STEMI). We investigated the effect of clopidogrel plus aspirin on tissue perfusion and coronary flow in infarct patients treated with fibrinolytic agents. Methods Consecutive 78 patients with STEMI were randomized to receive clopidogrel plus aspirin (clopidogrel group, n = 42) or placebo plus aspirin (placebo group, n = 36) before streptokinase. Maximum and total ST-segment resolutions (sumSTR) were calculated at 90 minutes after fibrinolysis. TIMI flow grade and corrected TIMI frame count in infarct-related artery were evaluated at predischarge. Inhospital ischemic and hemorrhagic events were also analyzed. Results Baseline characteristics were comparable in both groups. Both mean maximum ST-segment resolution (54.5 +/- 21.3% vs 44.6 +/- 22.0%, P =.047) and sumSTR (52.7 +/- 21.1% vs 42.8 +/- 20.7%, P =.041) were slightly higher in the clopidogrel group than placebo group. The rate of complete sumSTR 70% was significantly higher in the clopidogrel group compared with placebo group (31% vs 11%, P =.021). TIMI flows were similar in both groups, but corrected TIMI frame count was significantly lower in the clopidogrel group compared with placebo group (25.5 +/- 10.5 vs 33.5 +/- 11.8 frames, P =.027). Clinical events were comparable in 2 groups; however, there were 1 death caused by heart failure and moderate bleeding in the clopidogrel group. Conclusion Our results suggest that clopidogrel plus aspirin compared with aspirin alone may improve myocardial tissue perfusion and coronary flow in STEMI patients receiving streptokinase.
引用
收藏
页码:1037 / 1042
页数:6
相关论文
共 27 条
[1]   Predicting outcome after thrombolysis in acute myocardial infarction according to ST-segment resolution at 90 minutes: A substudy of the GUSTO-III trial [J].
Anderson, RD ;
White, HD ;
Ohman, EM ;
Wagner, GS ;
Krucoff, MW ;
Armstrong, PW ;
Weaver, WD ;
Gibler, WB ;
Stebbins, AL ;
Califf, RM ;
Topol, EJ .
AMERICAN HEART JOURNAL, 2002, 144 (01) :81-88
[2]   Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14 [J].
Antman, EM ;
Gibson, CM ;
de Lemos, JA ;
Giugliano, RP ;
McCabe, CH ;
Coussement, P ;
Menown, I ;
Nienaber, CA ;
Rehders, TC ;
Frey, NJ ;
Van der Wieken, R ;
Andresen, D ;
Scherer, J ;
Anderson, K ;
Van de Werf, F ;
Braunwald, E .
EUROPEAN HEART JOURNAL, 2000, 21 (23) :1944-1953
[3]   Determinants of improvement in epicardial flow and myocardial perfusion for ST elevation myocardial infarction - Insights from TIMI 14 and InTIME-II [J].
Antman, EM ;
Cooper, HA ;
Gibson, CM ;
de Lemos, JA ;
McCabe, CH ;
Giugliano, RP ;
Coussement, P ;
Murphy, S ;
Scherer, J ;
Anderson, K ;
Van de Werf, F ;
Braunwald, E .
EUROPEAN HEART JOURNAL, 2002, 23 (12) :928-933
[4]   Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction - Results of the ENTIRE-thrombolysis in myocardial infarction (TIMI) 23 trial [J].
Antman, EM ;
Louwerenburg, HW ;
Baars, HF ;
Wesdorp, JCL ;
Hamer, B ;
Bassand, JP ;
Bigonzi, F ;
Pisapia, G ;
Gibson, CM ;
Heidbuchel, H ;
Braunwald, E ;
Van de Werf, F .
CIRCULATION, 2002, 105 (14) :1642-1649
[5]   INDICATIONS FOR FIBRINOLYTIC THERAPY IN SUSPECTED ACUTE MYOCARDIAL-INFARCTION - COLLABORATIVE OVERVIEW OF EARLY MORTALITY AND MAJOR MORBIDITY RESULTS FROM ALL RANDOMIZED TRIALS OF MORE THAN 1000 PATIENTS [J].
APPLEBY, P ;
BAIGENT, C ;
COLLINS, R ;
FLATHER, M ;
PARISH, S ;
PETO, R ;
BELL, P ;
HALLS, H ;
MEAD, G ;
DIAZ, R ;
PAOLASSO, E ;
PAVIOTTI, C ;
ROMERO, G ;
CAMPBELL, T ;
OROURKE, MF ;
THOMPSON, P ;
LESAFFRE, E ;
VANDEWERF, F ;
VERSTRAETE, M ;
ARMSTRONG, PW ;
CAIRNS, JA ;
MORAN, C ;
TURPIE, AG ;
YUSUF, S ;
GRANDE, P ;
HEIKKILA, J ;
KALA, R ;
BASSAND, JP ;
BOISSEL, JP ;
BROCHIER, M ;
LEIZOROVICZ, A ;
BRUGGEMANN, T ;
KARSCH, KR ;
KASPER, W ;
LAMMERTS, D ;
NEUHAUS, KL ;
MEYER, J ;
SCHRODER, R ;
VONESSEN, R ;
SARAN, RK ;
ARDISSINO, D ;
BONADUCE, D ;
BRUNELLI, C ;
CERNIGLIARO, C ;
FORESTI, A ;
FRANZOSI, MG ;
GUIDUCCI, D ;
MAGGIONI, A ;
MAGNANI, B ;
MATTIOLI, G .
LANCET, 1994, 343 (8893) :311-322
[6]  
Bassand JP, 1999, SEMIN THROMB HEMOST, V25, P69
[7]   Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (Recombinant plasminogen activator) and front-loaded, accelerated alteplase (Recombinant tissue plasminogen activator) in patients with acute myocardial infarction [J].
Bode, C ;
Smalling, RW ;
Berg, G ;
Burnett, C ;
Lorch, G ;
Kalbfleisch, JM ;
Chernoff, R ;
Christie, LG ;
Feldman, RL ;
Seals, AA ;
Weaver, WD .
CIRCULATION, 1996, 94 (05) :891-898
[8]   Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction - The integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial [J].
Brener, SJ ;
Zeymer, U ;
Adgey, AAJ ;
Vrobel, TR ;
Ellis, SG ;
Neuhaus, KL ;
Juran, N ;
Ivanc, TB ;
Ohman, EM ;
Strony, J ;
Kitt, M ;
Topol, EJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (03) :377-386
[9]   TNK tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction - Results of the TIMI 10B trial [J].
Cannon, CP ;
Gibson, CM ;
McCabe, CH ;
Adgey, AAJ ;
Schweiger, MJ ;
Sequeira, RF ;
Grollier, G ;
Giugliano, RP ;
Frey, M ;
Mueller, HS ;
Steingart, RM ;
Weaver, WD ;
Van de Werf, F ;
Braunwald, E .
CIRCULATION, 1998, 98 (25) :2805-2814
[10]  
COLLER BS, 1992, ANNU REV MED, V43, P171